{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:25:40Z","timestamp":1795022740347,"version":"4.10.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    Biomarker-driven therapies have led to several recent advances in treating gastric and gastroesophageal junction (GEJ) cancers, but the overlap of these biomarkers remains unclear. We analyzed coexpression of Claudin 18.2 (CLDN18.2), HER2, PD-L1, and mismatch repair (MMR), focusing on CLDN18.2 staining extent and clinicopathologic correlations in gastric and GEJ adenocarcinomas. A total of 145 cases from 2023 to 2024 were identified from pathology archives. Following published clinical trial criteria, tumors were considered CLDN18.2-positive if \u226575% of tumor cells showed moderate-to-strong membranous staining. CLDN18.2 positivity was observed in 70 cases (48%) and was enriched in tumors with signet-ring-cell features (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0391, univariate;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0113, multivariate). No significant correlation was found with other clinicopathologic features or HER2, PD-L1, or MMR status. The inclusion of CLDN18.2 increased the proportion of cases with at least one actionable biomarker to 92%. Among triple-negative (HER2-negative, PD-L1-negative, and MMR-proficient) tumors, CLDN18.2 was positive in 52% overall and 50% of cases with metastasis, suggesting its potential utility in expanding treatment options. CLDN18.2 appeared to demonstrate relatively low intratumoral heterogeneity, with most tumors (72%) demonstrating either no staining (&lt;10% tumor cells staining) or diffuse staining (\u226590% of tumor cells staining). Among tumors classified as CLDN18.2-positive on the above criteria, 84% displayed homogeneous positivity. Nevertheless, heterogeneous expression was observed in a small percentage of tumors (28% of all tumors), indicating that sampling-related misclassification remains a potential concern. Our study provides detailed insights into CLDN18.2 expression and sheds light on the biomarker landscape in gastric and GEJ cancers.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002464","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:00:06Z","timestamp":1756288806000},"page":"1233-1244","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas"],"prefix":"10.1097","volume":"49","author":[{"given":"Bella L.","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cleary","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"R1-20251112","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20251112","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3748\/wjg.v12.i2.204","article-title":"Chemotherapy for gastric cancer","volume":"12","author":"Sastre","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"suppl 15","key":"R3-20251112","first-page":"12","article-title":"Chemotherapy in esophageal cancer","volume":"26","author":"Enzinger","year":"1999","journal-title":"Semin Oncol"},{"key":"R4-20251112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"R5-20251112","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"R6-20251112","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","article-title":"Claudins and the modulation of tight junction permeability","volume":"93","author":"G\u00fcnzel","year":"2013","journal-title":"Physiol Rev"},{"key":"R7-20251112","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"R8-20251112","first-page":"17","article-title":"A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"R9-20251112","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"R10-20251112","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"R11-20251112","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"R12-20251112","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"key":"R13-20251112","first-page":"100589","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"R14-20251112","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R15-20251112","doi-asserted-by":"crossref","first-page":"100778","DOI":"10.1016\/j.esmoop.2022.100778","article-title":"Claudin18.who? Examining biomarker overlap and outcomes in Claudin18.2-positive gastroesophageal adenocarcinomas","volume":"8","author":"Klempner","year":"2023","journal-title":"ESMO Open"},{"key":"R16-20251112","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas","volume":"11","author":"Pellino","year":"2021","journal-title":"J Pers Med"},{"key":"R17-20251112","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of Claudin18.2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res"},{"key":"R18-20251112","doi-asserted-by":"crossref","first-page":"e2300543","DOI":"10.1200\/PO.23.00543","article-title":"Retrospective study of Claudin 18 Isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma","volume":"8","author":"Waters","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R19-20251112","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer Off J Int"},{"key":"R20-20251112","first-page":"2357","article-title":"Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas","volume":"22","author":"Arnold","year":"2020","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"R21-20251112","doi-asserted-by":"crossref","first-page":"1453906","DOI":"10.3389\/fonc.2024.1453906","article-title":"Clinicopathological significance and prognostic values of claudin18.2 expression in solid tumors: a systematic review and meta-analysis","volume":"14","author":"Park","year":"2024","journal-title":"Front Oncol"},{"key":"R22-20251112","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"key":"R23-20251112","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1369\/jhc.2009.953810","article-title":"Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling","volume":"57","author":"Shinozaki","year":"2009","journal-title":"J Histochem Cytochem Off J Histochem Soc"},{"key":"R24-20251112","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"R25-20251112","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"R26-20251112","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1038\/s41598-023-47178-6","article-title":"Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"R27-20251112","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.21037\/tcr-19-1876","article-title":"Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"Transl Cancer Res"},{"key":"R28-20251112","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","article-title":"Prognostic value of claudin 18.2 expression in gastric adenocarcinoma","volume":"15","author":"Kayikcioglu","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"R29-20251112","doi-asserted-by":"crossref","first-page":"155628","DOI":"10.1016\/j.prp.2024.155628","article-title":"Expression of Claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients","volume":"263","author":"Kim","year":"2024","journal-title":"Pathol Res Pract"},{"key":"R30-20251112","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.12998\/wjcc.v7.i15.1964","article-title":"HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer","volume":"7","author":"Kaito","year":"2019","journal-title":"World J Clin Cases"},{"key":"R31-20251112","first-page":"1448","article-title":"Clinical significance of intratumoral HER2 heterogeneity in gastric cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"R32-20251112","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","article-title":"Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer","volume":"18","author":"Kurokawa","year":"2015","journal-title":"Gastric Cancer Off J Int"},{"key":"R33-20251112","doi-asserted-by":"crossref","first-page":"38372","DOI":"10.18632\/oncotarget.5368","article-title":"Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens","volume":"6","author":"Ahn","year":"2015","journal-title":"Oncotarget"},{"key":"R34-20251112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10120-018-0887-x","article-title":"Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer","volume":"22","author":"Yagi","year":"2019","journal-title":"Gastric Cancer Off J Int"},{"key":"R35-20251112","doi-asserted-by":"crossref","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"key":"R36-20251112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in Claudin 18.2 expression between primary and metastatic lesions in patients with gastric cancer","volume":"25","author":"Son","year":"2025","journal-title":"J Gastric Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:00:44Z","timestamp":1762927244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002464","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}